Eton Pharmaceuticals Inc. has released a corporate presentation detailing its progress and strategies in the ultra-rare disease sector. The company has built one of the broadest portfolios in the industry, with 13 products at various stages from CMC development to commercial availability. Key products include INCRELEX® for Severe Primary Insulin-Like Growth Factor 1 Deficiency and ALKINDI SPRINKLE® for Pediatric Adrenal Insufficiency. Eton highlights its successful internal development and high-ROI acquisitions, such as GALZIN® for Wilson disease and Carglumic Acid for Hyperammonemia. The company also mentions additional programs in late-stage development, reinforcing its position for long-term growth. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。